ArticleCureus2025
Impact of Neoadjuvant Chemotherapy on Skeletal Muscle Mass in Colorectal Cancer Patients Undergoing Curative Surgical Resection: A Single-Centre Retrospective Observational Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Neoadjuvant chemotherapy is often given before surgery in colorectal cancer to improve tumour resectability. However, its effects on skeletal muscle mass, which may influence post-operative recovery and functional outcomes, remain unclear. This study evaluates the impact of neoadjuvant chemotherapy on skeletal muscle mass in colorectal cancer patients undergoing curative surgery. Aim The aim of this study is to assess the effect of neoadjuvant chemotherapy on skeletal muscle mass in patients with colorectal cancer undergoing curative surgical resection. Methods A total of 100 patients who underwent surgical treatment for colorectal cancer between 2017 and 2022 were randomised into two groups: a chemotherapy group (n=50) that received neoadjuvant chemotherapy and a control group (n=50) that underwent surgery alone. Skeletal muscle area (cm²) was measured using CT scans both pre- and post-operatively: rectus abdominis at L1 and psoas at L4. Values were normalised for patient height squared to derive the skeletal muscle index (cm²/m²). Post-operative complications were recorded. Results The study enrolled 100 patients (median age 66.7 years, IQR 13.46; 58% male). No significant reduction in rectus or psoas muscle mass was observed pre- and post-chemotherapy in the treatment group (rectus: 4.33±3.8 vs. 4.03±1.96, p=0.567; psoas: 8.85±1.97 vs. 8.91±1.96; p=0.745). Baseline rectus muscle mass was comparable between groups (4.33±3.8 vs. 4.8±2.06; p=0.444). Post-operatively, the chemotherapy group showed lower rectus and psoas muscle mass compared to controls (rectus: 3.77±1.36 vs. 4.52±1.66, p=0.016; psoas: 9.09±1.93 vs. 10.13±2.86; p=0.037). No significant differences in pre- and post-treatment muscle mass change between groups (p>0.05). The chemotherapy group reported a higher incidence of falls (12% vs. 0%, p=0.027) and post-operative muscle weakness (22% vs. 0%, p=0.0004). Conclusion Neoadjuvant chemotherapy did not significantly impact short-term muscle mass loss in colorectal cancer patients undergoing curative surgery. However, a higher incidence of post-operative functional decline was observed, warranting further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.